Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Improving Margins ⢠Strong Liquidity ⢠Persistent Cash Burn PLSE's improving gross margins, strong liquidity, and low debt are offset by severe losses, cash burn, equity-funded dilution, and an exceptionally high valuation relative to revenue.
Price Behavior
Key Price Behavior Insights: ⢠Strong uptrend ⢠Stretched momentum ⢠Key $50 support Support Level: $50.00â$52.00 (secondary: $47.50â$49.00) Resistance Level: $54.70â$55.00 PLSE surged 25.5% over the last month and remains bullish above $50.00 support, but near-$55.00 resistance and stretched momentum suggest avoiding chasing without a pullback.
Sentiment & News
Key News Insights: ⢠Earnings Miss ⢠Strong Liquidity ⢠Institutional Interest Pulse Biosciences missed Q2 earnings and revenue expectations, but strong cash reserves, fresh financing, and institutional interest support continued nsPFA clinical-development momentum.
AI Summary
PLSE is a high-valuation clinical optionânot a proven commercial businessâwhere rapid NANOPULSE-AF enrollment supports execution but only differentiated safety and efficacy data can justify its ~$2.7B value; investors should await clinical and regulatory validation, as delays or merely adequate results could trigger sharp valuation compression and further dilution.
Description
Pulse Biosciences, Inc. is a bioelectric medicine company that develops the CellFX System, a console-based platform that delivers nanosecond electrical pulses (Nano-Pulse Stimulation) to non-thermally remove targeted cells while sparing surrounding non-cellular tissue. The company was incorporated in 2014, changed its name from Electroblate, Inc. to Pulse Biosciences in December 2015, and is headquartered in Hayward, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 18 | Feb 25 | PLSE | Pulse Biosciences, Inc. | High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name. | Closed | -24.6% |
| Feb 11 | Feb 18 | PLSE | Pulse Biosciences, Inc. | FDA IDEs for NANOPULSEâAF and nPulse 360 EP plus strong firstâinâhuman ablation data (150 patients, presented 2026â02â05) triggered a ~75% threeâday jump and price ~55% above its 21âday SMA, making PLSE a highâvolatility clinicalâcatalyst momentum trade into the 2026â02â19 earnings update. | Closed | +0.8% |